Intravenous administration of Type II collagen to rats prior to immunization with Type II collagen suppresses hind paw inflammation, humoral response to Type II collagen, and the severity of the arthritic lesion. Suppression of inflammation and its severity as well as the humoral response can also be induced by the prior intravenous administration of α1 (II) CB10 a cyanogen bromide peptide derived from Type II collagen. Suppression of arthritis is disease specific; intravenous administration of either Type II collagen or α1 (II) CB10 does not have an effect on adjuvant-induced arthritis. These studies indicate that structural determinants of α1 (II) CB10 (Mr, 30,000), a peptide located near the carboxy terminus of the collagen molecule, can induce suppression and suggest that these determinants may be responsible for the suppression of arthritis when Type II collagen is administered intravenously.
ASJC Scopus subject areas